文献速递消化道肿瘤与早癌

不可切除结直肠癌肝转移患者接受贝伐珠单抗治疗时早期影像学预后预测指标的对比

Comparison of early radiological predictors of outcome in patients with colorectal cancer with unresectable hepatic metastases treated with bevacizumab.
PubMed 文献 · Gut · 2017-10-30

该研究回顾性分析141例一线接受贝伐珠单抗治疗和142例来自评估贝伐珠单抗联合奥沙利铂化疗随机研究的不可切除结直肠癌肝转移患者,用形态学反应标准和基于大小的标准评估早期CT反应。结果显示,达到最佳形态学反应者中位无进展生存期显著更长,RECIST和早期肿瘤缩小反应均与无进展生存期延长无关;贝伐珠单抗组达到最佳形态学反应的可能性为对照组的6.2倍。

要点

  • 在两组人群中,达到最佳形态学反应者的中位无进展生存期均显著更长。
  • RECIST反应和早期肿瘤缩小反应均与无进展生存期延长无关。
  • 在随机研究中,接受贝伐珠单抗的患者达到最佳形态学反应的可能性为对照组的6.2倍。

核心结论

  • 在不可切除结直肠癌肝转移患者中,早期形态学反应可能比基于大小的反应更好地预测无进展生存期。
  • 加用贝伐珠单抗可提高形态学反应率。

研究设计与样本

  • 回顾性分析141例一线接受贝伐珠单抗治疗的患者和142例来自评估贝伐珠单抗联合奥沙利铂化疗随机研究的患者。
  • 放射科医生使用形态学反应标准评估治疗前和再分期CT扫描。
  • 同时使用基于大小的标准评估反应:实体瘤疗效评价标准(RECIST)、早期肿瘤缩小(ETS)和缓解深度(DpR)。
  • 采用单变量Cox比例风险模型确定各标准预测无进展生存期(PFS)、总生存期(OS)和进展后生存期(PPS)的能力。

主要发现

  • 在两组人群中,达到最佳形态学反应者的中位PFS显著更长:第一组为10.4个月 vs 6.8个月(p=0.03),第二组为8.3个月 vs 4.9个月(p<0.0001)。
  • RECIST反应和ETS反应均与PFS延长无关。
  • 在第一组人群(n=141)中,仅在第二次再分期时,达到最佳形态学反应者的中位OS更长(20.8个月 vs 12.3个月,p=0.002)。
  • DpR与PPS相关,而最佳形态学反应与PPS无关。
  • 在随机研究中,接受贝伐珠单抗的患者达到最佳形态学反应的可能性为对照组的6.2倍(p<0.0001)。

关键数值与推荐

  • 最佳形态学反应:第一组中位PFS 10.4个月 vs 6.8个月(p=0.03);第二组中位PFS 8.3个月 vs 4.9个月(p<0.0001)。
  • 最佳形态学反应:第一组第二次再分期时中位OS 20.8个月 vs 12.3个月(p=0.002,n=141)。
  • 随机研究中,接受贝伐珠单抗者达到最佳形态学反应的可能性为对照组的6.2倍(p<0.0001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The purpose was to validate the prognostic value of an early optimal morphological response on CT in patients treated with bevacizumab-containing chemotherapy for unresectable colorectal cancer liver metastases (CLM). It also evaluated the prognostic value of size-based criteria and the association of optimal morphological response with the receipt of bevacizumab. DESIGN: 141 patients treated first using bevacizumab and 142 patients from a randomised study evaluating the addition of bevacizumab to oxaliplatin-based chemotherapy were retrospectively analysed. Radiologists evaluated pretreatment and restaging CT scans using morphological response criteria. Responses were also assessed with size-based criteria: Response Evaluation Criteria in Solid Tumors (RECIST), early tumour shrinkage (ETS) and deepness of response (DpR). The ability of each criterion to predict progression-free survival (PFS), overall survival (OS) and postprogression survival (PPS) was determined using a univariate Cox proportional hazards model. RESULTS: In both populations, median PFS was significantly longer for patients achieving an optimal morphological response (10.4 vs 6.8 months, p=0.03; and 8.3 vs 4.9 months, p<00001, respectively). Neither RECIST nor ETS responses were associated with a prolonged PFS. Median OS was longer for those with an optimal morphological response but only at second restaging in the first population (n=141, 20.8 vs 12.3 months, p=0.002). DpR but not optimal morphological response was associated with PPS. In the randomised study, an optimal morphological response was 6.2 times more likely among patients receiving bevacizumab (p<0.0001). CONCLUSION: In patients with unresectable CLM, early morphological response may be a better predictor of PFS than size-based response. The addition of bevacizumab improves morphological response rate.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Mazard T, Boonsirikamchai P, Overman MJ, et al. Comparison of early radiological predictors of outcome in patients with colorectal cancer with unresectable hepatic metastases treated with bevacizumab. Gut. 2017. PMID: 29084828. doi:10.1136/gutjnl-2017-313786

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。